Europe’s drug patent clock is ticking—here’s where it actually stops.
If you’re building a pipeline, underwriting risk, or planning market entry in Europe, you already know the headline: patents “last” a certain number of years. But in practice, the re…
European Drug Patents: Exactly How Long Protection Lasts — and Where It Breaks Down Read Post »
Drug discovery timelines are getting longer—and the cost of waiting is getting higher. The industry has spent years optimizing molecules, assays, and pipelines, but the bottleneck is increasingly upstream: how quickly teams can translate messy biology …
Slash drug discovery timelines with GPT-Rosalind Read Post »
The “Patent Expiration Cliff” Isn’t a Cliff—It’s a Calendar. Here’s How Commercial Teams Can Stop Getting Blindsided.
If you work in commercial market access, you’ve probably felt it: the sudden pressure when a branded product’s exclusivity window star…
Authorized Generics: The Innovator’s Playbook for Diluting First-Filer Profits
The first-filer advantage is supposed to be a clean win: take the risk, challenge the patent, earn exclusivity, and capture meaningful market share before competitors arrive…
Authorized Generics: The Innovator’s Playbook for Diluting First-Filer Profits Read Post »
The clock is ticking—and “generic” isn’t one-size-fits-all.
If you’re building a true generic entry strategy, the biggest risk isn’t regulatory delay—it’s timing miscalculation. In today’s exclusivity landscape, “launch when the patent expires” is ofte…
Unlocking the Hidden Clock: How Precise Mapping of Regulatory Exclusivities Can Accelerate Generic Drug Entry
In the complex world of pharmaceutical innovation and market competition, timing is everything. Yet, for many stakeholders—manufacturers, inve…
The real “winner” in generic drug launches isn’t the company with the best science—it’s the company that wins the patent clock.
If you’ve ever wondered why some medicines hit the market faster than others—or why certain generics seem to get delayed eve…
Consumers Pay a “Trust Premium” for Branded Generics—And It’s Not Just Marketing
Walk into any pharmacy and you’ll see it: two pills, two prices, one decision. Branded generics often cost more than their “plain” generic counterparts—even when the activ…
Why Consumers Pay a “Trust Premium” for Branded Generics Read Post »
AI is starting to “know” your drug the way competitors do. The question is whether you’ll use that knowledge—or be surprised by it.
In pharma, we’ve spent years building competitive advantage the old-fashioned way: clinical differentiation, manufacturi…
What AI Knows About Your Drug vs. Your Competitors Read Post »
Most pharma teams don’t lose the patent race because they don’t care about IP.
They lose because they’re looking in the wrong place—at the wrong time—with the wrong questions.
That’s the uncomfortable truth behind the “intelligence gap” highlighted in …
Read the Patent, Beat the Competition: The Intelligence Gap Most Pharma Teams Leave Open Read Post »
Get new actionable insights and updates from BiotechBlog
